Bulgaria vs Tunisia: Average cost of multi drug-resistant tuberculosis treatment
Bulgaria
6,271 constant 2022 US$
in 2024
Tunisia
4,560 constant 2022 US$
in 2023
Bulgaria rank
6th
Tunisia rank
9th
Average cost of multi drug-resistant tuberculosis treatment over time
- Bulgaria
- Tunisia
How they compare
Bulgaria currently reports 6,271 constant 2022 US$ against 4,560 constant 2022 US$ in Tunisia, a difference of 1,711 constant 2022 US$.
That makes Bulgaria's figure about 1.4 times Tunisia's.
The two have swapped places 3 times across 5 shared years of data; in 2018 it was Tunisia ahead.
Bulgaria ranks 6th and Tunisia ranks 9th of 92 countries.
Across the 2 decades both report, Bulgaria averaged higher in 1 and Tunisia in 1.
Head to head by decade
| Decade | Bulgaria | Tunisia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,308 constant 2022 US$ | 5,000 constant 2022 US$ | 3,692 constant 2022 US$ | Tunisia |
| 2020s | 4,482 constant 2022 US$ | 3,665 constant 2022 US$ | 817 constant 2022 US$ | Bulgaria |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Bulgaria or Tunisia?
- Bulgaria, at 6,271 constant 2022 US$ against 4,560 constant 2022 US$ in Tunisia as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Bulgaria and Tunisia?
- 1,711 constant 2022 US$, with Bulgaria ahead.
- How many years of comparable data are there for Bulgaria and Tunisia?
- 5 years are reported by both, from 2018 to 2023.
- How do Bulgaria and Tunisia rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Bulgaria ranks 6th and Tunisia ranks 9th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.